Back to Agenda
Session 20: Benefit-Risk
Session Chair(s)
William Gregory, PhD
Senior Director, Safety and Risk Management
Pfizer Inc, United States
This session will address the concepts that encompass stakeholder perceptions in the iterative assessment of benefit-risk. Several models of structured benefit-risk assessment, as well as FDA’s current approach to benefit-risk, will be explained. The session will conclude with an introduction to risk communication.
Have an account?